Evidence Report/Technology Assessment Number 84

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

File Inventory


Prepared by:

Johns Hopkins Evidence-based Practice Center

Sherita Golden, M.D., M.H.S.
L. Ebony Boulware, M.D., M.P.H.
   Co-Principal Investigators
Gail Berkenblit, M.D., Ph.D.
Frederick L. Brancati, M.D., M.H.S.
Geetanjali Chander, M.D., M.P.H.
Spyridon Marinopoulos, M.D., M.B.A.
Michael Paasche-Orlow, M.D., M.P.H.
Neil Powe, M.D., M.P.H., M.B.A
Tejal Rami, M.P.H.
   Investigators


File Name	Description			Software	Version	File	Size
________________________________________________________________________________________________
01front.doc	Microsoft Word® Document	MS Word®	2002	35KB	3 pages
Contents: Title Page, Preface
________________________________________________________________________________________________
02abstr.doc	Microsoft Word® Document	MS Word®	2002	23KB	2 pages
Contents: Structured Abstract
________________________________________________________________________________________________
03conts.doc	Microsoft Word® Document	MS Word®	2002	32KB	3 pages
Contents: Table of Contents
________________________________________________________________________________________________
04summ.doc	Microsoft Word® Document	MS Word®	2002	67KB	9 pages
Contents: Summary
________________________________________________________________________________________________
05chap1.doc	Microsoft Word® Document	MS Word®	2002	87KB	7 pages
Contents: Chapter 1. Introduction: Background, Key Questions
________________________________________________________________________________________________
06chap2.doc	Microsoft Word® Document	MS Word®	2002	45KB	6 pages
Contents: Chapter 2. Methodology: Recruitment of Technical Experts and Peer Reviewers, 
Process of Systematic Review, Glycemic Control, Urine Albumin, Assessment of Study Quality, 
Calculation of Weighted Averages
________________________________________________________________________________________________
07chap3.doc	Microsoft Word® Document	MS Word®	2002	449KB	46 pages
Contents: Chapter 3. Results: Glycemic Control, Urine Albumin
________________________________________________________________________________________________
08chap4.doc	Microsoft Word® Document	MS Word®	2002	37KB	5 pages
Contents: Chapter 4. Conclusions and Limitations: Glycemic Control, Urine Albumin
________________________________________________________________________________________________
09chap5.doc	Microsoft Word® Document	MS Word®	2002	29KB	2 pages
Contents: Chapter 5. Future Research: Glycemic Control, Urine Albumin
________________________________________________________________________________________________
10refs.doc	Microsoft Word® Document	MS Word®	2002	82KB	11 pages
Contents: References
________________________________________________________________________________________________
11etbl1.doc	Microsoft Word® Document	MS Word®	2002	295KB	17 pages
Contents: Evidence Table 1. Study Population, Design, Location, Recruitment, Outcomes, Quality
________________________________________________________________________________________________
12etbl2.doc	Microsoft Word® Document	MS Word®	2002	614KB	23 pages
Contents: Evidence Table 2. Baseline Data for All Study Participants; Cohort Studies
________________________________________________________________________________________________
13etbl3.doc	Microsoft Word® Document	MS Word®	2002	104KB	3 pages
Contents: Evidence Table 3. Baseline Data for All Study Participants; Randomized Controlled Trials
________________________________________________________________________________________________
14etbl4.doc	Microsoft Word® Document	MS Word®	2002	408KB	12 pages
Contents: Evidence Table 4. Diagnosis of Diabetes; Cohort Studies
________________________________________________________________________________________________
15etbl5.doc	Microsoft Word® Document	MS Word®	2002	41KB	1 page
Contents: Evidence Table 5. Diagnosis of Diabetes; Randomized Controlled Trials
________________________________________________________________________________________________
16etbl6.doc	Microsoft Word® Document	MS Word®	2002	120KB	3 pages
Contents: Evidence Table 6. Retinopathy: Cohort Studies: Incident Retinopathy, type 1 diabetes
________________________________________________________________________________________________
17etbl7.doc	Microsoft Word® Document	MS Word®	2002	141KB	4 pages
Contents: Evidence Table 7. Retinopathy: Cohort Studies: Incident Retinopathy, type 2 diabetes
________________________________________________________________________________________________
18etbl8.doc	Microsoft Word® Document	MS Word®	2002	140KB	6 pages
Contents: Evidence Table 8. Retinopathy: Cohort Studies: Incident Proliferate Retinopathy/
Macular Edema, type 1 diabetes
________________________________________________________________________________________________
19etbl9.doc	Microsoft Word® Document	MS Word®	2002	111KB	4 pages
Contents: Evidence Table 9. Retinopathy: Cohort Studies: Incident Proliferate Retinopathy/
Macular Edema, type 2 diabetes
________________________________________________________________________________________________
20etbl10.doc	Microsoft Word® Document	MS Word®	2002	146KB	5 pages
Contents: Evidence Table 10. Retinopathy: Cohort Studies: Progression of Retinopathy, 
type 1 diabetes
________________________________________________________________________________________________
21etbl11.doc	Microsoft Word® Document	MS Word®	2002	93KB	3 pages
Contents: Evidence Table 11. Retinopathy: Cohort Studies: Progression of Retinopathy, 
type 2 diabetes
________________________________________________________________________________________________
22etbl12.doc	Microsoft Word® Document	MS Word®	2002	59KB	2 pages
Contents: Evidence Table 12. Retinopathy: Cohort Studies: Blindness/ Visual Acuity, 
type 1 diabetes
________________________________________________________________________________________________
23etbl13.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 13. Retinopathy: Cohort Studies: Blindness / Visual Acuity, 
type 2 diabetes
________________________________________________________________________________________________
24etbl14.doc	Microsoft Word® Document	MS Word®	2002	57KB	2 pages
Contents: Evidence Table 14. Retinopathy: Cohort Studies: Cataract Extraction, type 2 diabetes
________________________________________________________________________________________________
25etbl15.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 15. Retinopathy: Randomized Controlled Trials: Incident Retinopathy, 
type 1 diabetes
________________________________________________________________________________________________
26etbl16.doc	Microsoft Word® Document	MS Word®	2002	32KB	1 page
Contents: Evidence Table 16. Retinopathy: Randomized Controlled Trials: Incident Retinopathy, 
type 2 diabetes
________________________________________________________________________________________________
27etbl17.doc	Microsoft Word® Document	MS Word®	2002	32KB	1 page
Contents: Evidence Table 17. Retinopathy: Randomized Controlled Trials: Incident Proliferative 
Retinopathy, type 1 diabetes
________________________________________________________________________________________________
28etbl18.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 18. Retinopathy: Randomized Controlled Trials: Incident Proliferative 
Retinopathy, type 2 diabetes
________________________________________________________________________________________________
29etbl19.doc	Microsoft Word® Document	MS Word®	2002	53KB	2 pages
Contents: Evidence Table 19. Retinopathy: Randomized Controlled Trials: Progression of Retinopathy, 
type 1 diabetes
________________________________________________________________________________________________
30etbl20.doc	Microsoft Word® Document	MS Word®	2002	49KB	2 pages
Contents: Evidence Table 20. Retinopathy: Randomized Controlled Trials: Progression of Retinopathy, 
type 2 diabetes
________________________________________________________________________________________________
31etbl21.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 21. Retinopathy: Randomized Controlled Trials: Blindness / Visual Acuity, 
type 1 diabetes
________________________________________________________________________________________________
32etbl22.doc	Microsoft Word® Document	MS Word®	2002	35KB	1 page
Contents: Evidence Table 22. Retinopathy: Randomized Controlled Trials: Blindness / Visual Acuity, 
type 2 diabetes
________________________________________________________________________________________________
33etbl23.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 23. Retinopathy: Randomized Controlled Trials: Cataract Extraction, 
type 2 diabetes
________________________________________________________________________________________________
34etbl24.doc	Microsoft Word® Document	MS Word®	2002	170KB	7 pages
Contents: Evidence Table 24. Nephropathy: Cohort Studies: Incidence/Progression of 
Microalbuminuria, type 1 diabetes
________________________________________________________________________________________________
35etbl25.doc	Microsoft Word® Document	MS Word®	2002	98KB	3 pages
Contents: Evidence Table 25. Nephropathy: Cohort Studies: Incidence/Progression of 
Microalbuminuria, type 2 diabetes
________________________________________________________________________________________________
36etbl26.doc	Microsoft Word® Document	MS Word®	2002	75KB	3 pages
Contents: Evidence Table 26. Nephropathy: Cohort Studies: Incidence/Progression of 
Macroalbuminuria, type 1 diabetes
________________________________________________________________________________________________
37etbl27.doc	Microsoft Word® Document	MS Word®	2002	46KB	2 pages
Contents: Evidence Table 27. Nephropathy: Cohort Studies Incidence/Progression of 
Macroalbuminuria (combined endpoint), type 2 diabetes
________________________________________________________________________________________________
38etbl28.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 28. Nephropathy: Cohort Studies: Progression of Nephropathy, 
type 1 diabetes
________________________________________________________________________________________________
39etbl29.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 29. Nephropathy: Cohort Studies: Progression of Nephropathy, 
type 2 diabetes
________________________________________________________________________________________________
40etbl30.doc	Microsoft Word® Document	MS Word®	2002	51KB	2 pages
Contents: Evidence Table 30. Nephropathy: Cohort Studies: Change in GFR/ Creatinine Clearance, 
type 1 diabetes
________________________________________________________________________________________________
41etbl31.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 31. Nephropathy: Cohort Studies: End-stage renal disease: 
Renal replacement therapy or transplant, type 1 diabetes
________________________________________________________________________________________________
42etbl32.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Evidence Table 32. Nephropathy: Cohort Studies: End-stage renal disease: 
Renal replacement therapy or transplant, type 2 diabetes
________________________________________________________________________________________________
43etbl33.doc	Microsoft Word® Document	MS Word®	2002	40KB	1 page
Contents: Evidence Table 33. Nephropathy: Randomized Controlled Trials: Incidence/Progression 
of Microalbuminuria, type 1 diabetes
________________________________________________________________________________________________
44etbl34.doc	Microsoft Word® Document	MS Word®	2002	46KB	2 pages
Contents: Evidence Table 34. Nephropathy: Randomized Controlled Trials: Incidence/Progression 
of Microalbuminuria, type 2 diabetes
________________________________________________________________________________________________
45etbl35.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 35. Nephropathy: Randomized Controlled Trials: Incidence/Progression 
of Macroalbuminuria, type 1 diabetes
________________________________________________________________________________________________
46etbl36.doc	Microsoft Word® Document	MS Word®	2002	42KB	1 page
Contents: Evidence Table 36. Nephropathy: Randomized Controlled Trials: Incidence/Progression 
of Macroalbuminuria, type 2 diabetes
________________________________________________________________________________________________
47etbl37.doc	Microsoft Word® Document	MS Word®	2002	30KB	1 page
Contents: Evidence Table 37. Nephropathy: Randomized Controlled Trials: Progression of Nephropathy, 
type 1 diabetes
________________________________________________________________________________________________
48etbl38.doc	Microsoft Word® Document	MS Word®	2002	31KB	1 page
Contents: Evidence Table 38. Nephropathy: Randomized Controlled Trials: Progression of Nephropathy, 
type 2 diabetes
________________________________________________________________________________________________
49etbl39.doc	Microsoft Word® Document	MS Word®	2002	65KB	2 pages
Contents: Evidence Table 39. Neuropathy: Cohort Study: Peripheral Neuropathy, type 1 diabetes
________________________________________________________________________________________________
50etbl40.doc	Microsoft Word® Document	MS Word®	2002	39KB	2 pages
Contents: Evidence Table 40. Neuropathy: Cohort Study: Peripheral Neuropathy, type 2 diabetes
________________________________________________________________________________________________
51etbl41.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 41. Neuropathy: Cohort Study: Autonomic Neuropathy, type 1 diabetes
________________________________________________________________________________________________
52etbl42.doc	Microsoft Word® Document	MS Word®	2002	56KB	2 pages
Contents: Evidence Table 42. Neuropathy: Randomized Controlled Trials: Peripheral Neuropathy, 
type 1 diabetes
________________________________________________________________________________________________
53etbl43.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 43. Neuropathy: Randomized Controlled Trials: Peripheral Neuropathy, 
type 2 diabetes
________________________________________________________________________________________________
54etbl44.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 44. Neuropathy: Randomized Controlled Trials: Autonomic Neuropathy, 
type 2 diabetes
________________________________________________________________________________________________
55etbl45.doc	Microsoft Word® Document	MS Word®	2002	39KB	1 page
Contents: Evidence Table 45. Macrovascular: Cause Specific Cardiovascular Morbidity-Coronary 
Artery Disease: Cohort Studies: Angina, Non-fatal Myocardial Infarction, type 2 diabetes
________________________________________________________________________________________________
56etbl46.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Evidence Table 46. Macrovascular: Cause Specific Cardiovascular Morbidity-Cerebrovascular 
Disease: Cohort Studies: Non-fatal Stroke, type 2 diabetes
________________________________________________________________________________________________
57etbl47.doc	Microsoft Word® Document	MS Word®	2002	84KB	3 pages
Contents: Evidence Table 47. Macrovascular: Cause Specific Cardiovascular Morbidity-Peripheral 
Arterial Disease: Cohort Studies: Non-fatal Peripheral Arterial Disease, type 1 diabetes
________________________________________________________________________________________________
58etbl48.doc	Microsoft Word® Document	MS Word®	2002	57KB	2 pages
Contents: Evidence Table 48. Macrovascular: Cause Specific Cardiovascular Morbidity-Peripheral 
Arterial Disease: Cohort Studies: Non-fatal Peripheral Arterial Disease, type 2 diabetes
________________________________________________________________________________________________
59etbl49.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 49. Macrovascular: Cause Specific Cardiovascular Morbidity-Congestive 
Heart Failure: Cohort Studies: Congestive Heart Failure, type 2 diabetes
________________________________________________________________________________________________
60etbl50.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 50. Macrovascular: Cause Specific Cardiovascular Morbidity-Carotid IMT: 
Cohort Studies: Carotid IMT, type 1 diabetes
________________________________________________________________________________________________
61etbl51.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Evidence Table 51. Macrovascular: Cause Specific Cardiovascular Morbidity-Carotid IMT: 
Cohort Studies: Carotid IMT, type 2 diabetes
________________________________________________________________________________________________
62etbl52.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 52. Macrovascular: Cause Specific Cardiovascular Mortality-Coronary 
Artery Disease: Cohort Studies: Fatal Myocardial Infarction, type 1 diabetes
________________________________________________________________________________________________
63etbl53.doc	Microsoft Word® Document	MS Word®	2002	48KB	2 pages
Contents: Evidence Table 53. Macrovascular: Cause Specific Cardiovascular Mortality-Coronary 
Artery Disease: Cohort Studies: Fatal Myocardial Infarction, type 2 diabetes
________________________________________________________________________________________________
64etbl54.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Evidence Table 54. Macrovascular: Cause Specific Cardiovascular Mortality-
Cerebrovascular Disease: Cohort Studies: Fatal Stroke, type 2 diabetes
________________________________________________________________________________________________
65etbl55.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Evidence Table 55. Macrovascular: Composite Cardiovascular Mortality-Fatal Myocardial 
Infarction or Stroke: Cohort Studies: Fatal Myocardial Infarction or Stroke, type 2 diabetes
________________________________________________________________________________________________
66etbl56.doc	Microsoft Word® Document	MS Word®	2002	33KB	1 page
Contents: Evidence Table 56. Macrovascular: Composite CVD Morbidity and Mortality-
Cardiovascular Disease: Cohort Studies: Fatal and Non-fatal Myocardial Infarction, type 1 diabetes
________________________________________________________________________________________________
67etbl57.doc	Microsoft Word® Document	MS Word®	2002	54KB	2 pages
Contents: Evidence Table 57. Macrovascular: Composite CVD Mortality-Cardiovascular Disease: 
Cohort Studies: Fatal and Non-fatal Myocardial Infarction, type 2 diabetes
________________________________________________________________________________________________
68etbl58.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Evidence Table 58. Macrovascular: Composite CVD Morbidity and Mortality-
Cerebrovascular Disease: Cohort Studies: Fatal and Non-fatal Stroke, type 1 diabetes
________________________________________________________________________________________________
69etbl59.doc	Microsoft Word® Document	MS Word®	2002	57KB	2 pages
Contents: Evidence Table 59. Macrovascular: Composite CVD Morbidity and Mortality-
Cerebrovascular Disease: Cohort Studies: Fatal and Non-fatal Stroke, type 2 diabetes
________________________________________________________________________________________________
70etbl60.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 60. Macrovascular: Composite CVD Morbidity and Mortality-
Cardiovascular Disease: Randomized Controlled Trial: Fatal and Non-fatal Myocardial Infarction, 
type 2 diabetes
________________________________________________________________________________________________
71etbl61.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 61. Macrovascular: Composite CVD Morbidity and Mortality- 
Cerebrovascular Disease: Randomized Controlled Trial: Fatal and Non-Fatal Stroke, type 2 diabetes
________________________________________________________________________________________________
72etbl62.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 62. Macrovascular: Composite CVD Morbidity and Mortality- 
Peripheral Arterial Disease: Randomized Controlled Trial: Fatal and Non-fatal peripheral 
vascular disease, type 2 diabetes
________________________________________________________________________________________________
73etbl63.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 63. Macrovascular Cause Specific Cardiovascular Morbidity-Congestive 
Heart Failure: Randomized Controlled Trial: Congestive Heart Failure, type 2 diabetes
________________________________________________________________________________________________
74etbl64.doc	Microsoft Word® Document	MS Word®	2002	37KB	2 pages
Contents: Evidence Table 64. Studies Examining Threshold Effect Between Glycosylated Hemoglobin 
and Retinopathy
________________________________________________________________________________________________
75etbl65.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 65. Studies Examining Threshold Effect Between Glycosylated Hemoglobin 
and Nephropathy
________________________________________________________________________________________________
76etbl66.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 66. Studies Examining Threshold Effect Between Glycosylated Hemoglobin 
and Neuropathy
________________________________________________________________________________________________
77etbl67.doc	Microsoft Word® Document	MS Word®	2002	25KB	1 page
Contents: Evidence Table 67. Studies Examining Threshold Effect Between Glycosylated Hemoglobin 
and Macrovascular Complications
________________________________________________________________________________________________
78etbl68.doc	Microsoft Word® Document	MS Word®	2002	117KB	5 pages
Contents: Evidence Table 68. Study Population, Design, Location, Recruitment, Outcomes, Quality
________________________________________________________________________________________________
79etbl69.doc	Microsoft Word® Document	MS Word®	2002	117KB	5 pages
Contents: Evidence Table 69. Baseline Data for All Study Participants; Cohort Studies
________________________________________________________________________________________________
80etbl70.doc	Microsoft Word® Document	MS Word®	2002	55KB	2 pages
Contents: Evidence Table 70. Baseline Data for All Study Participants; Randomized Controlled Trials
________________________________________________________________________________________________
81etbl71.doc	Microsoft Word® Document	MS Word®	2002	114KB	4 pages
Contents: Evidence Table 71. Diagnosis of Diabetes; Cohort Studies
________________________________________________________________________________________________
82etbl72.doc	Microsoft Word® Document	MS Word®	2002	31KB	1 page
Contents: Evidence Table 72. Diagnosis of Diabetes; Randomized Controlled Trials 
________________________________________________________________________________________________
83etbl73.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Evidence Table 73. Renal Outcomes; Cohort Studies: Change in GFR at Study Follow Up
________________________________________________________________________________________________
84etbl74.doc	Microsoft Word® Document	MS Word®	2002	38KB	1 page
Contents: Evidence Table 74. Renal Outcomes; Cohort Studies: Rate of Change in GFR
________________________________________________________________________________________________
85etbl75.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 75. Renal Outcomes; Cohort Studies: Rate of change of 1/serum creatinine 
________________________________________________________________________________________________
86etbl76.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 76. Renal Outcomes; Cohort Studies: Rate of change in creatinine clearance 
________________________________________________________________________________________________
87etbl77.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Evidence Table 77. Renal Outcomes; Cohort Studies: Incidence of ESRD, need for 
renal replacement therapy, or kidney transplantation
________________________________________________________________________________________________
88etbl78.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 78. Renal Outcomes; Randomized Controlled Trials: Change in GFR 
at Study Follow Up
________________________________________________________________________________________________
89etbl79.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Evidence Table 79. Renal Outcomes; Randomized Controlled Trials: Rate of Change in GFR
________________________________________________________________________________________________
90etbl80.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 80. Renal Outcomes; Randomized Controlled Trials: Change in Creatinine 
Clearance at Study Follow up
________________________________________________________________________________________________
91etbl81.doc	Microsoft Word® Document	MS Word®	2002	27KB	1 page
Contents: Evidence Table 81. Renal Outcomes; Randomized Controlled Trials: Rate of Change 
in Creatinine Clearance
________________________________________________________________________________________________
92etbl82.doc	Microsoft Word® Document	MS Word®	2002	48KB	1 page
Contents: Evidence Table 82. All Cause Mortality; Cohort Studies: type 1 diabetes
________________________________________________________________________________________________
93etbl83.doc	Microsoft Word® Document	MS Word®	2002	151KB	5 pages
Contents: Evidence Table 83. All Cause Mortality; Cohort Studies: type 2 diabetes
________________________________________________________________________________________________
94etbl84.doc	Microsoft Word® Document	MS Word®	2002	48KB	1 page
Contents: Evidence Table 84. All Cause Mortality; Cohort Studies: type 1 and 2 diabetes or 
Diabetes Type Not Specified (NOS)
________________________________________________________________________________________________
95etbl85.doc	Microsoft Word® Document	MS Word®	2002	45KB	1 page
Contents: Evidence Table 85. All Cause Mortality; Clinical Trials Analyzed as Cohort Studies:
type 1 and 2 diabetes or Diabetes Type Not Specified (NOS)
________________________________________________________________________________________________
96etbl86.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Evidence Table 86. All Cause Mortality; Randomized Controlled Trials: type 2 diabetes
________________________________________________________________________________________________
97etbl87.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 87. Composite CVD Mortality; Cohort Studies: type 1 diabetes
________________________________________________________________________________________________
98etbl88.doc	Microsoft Word® Document	MS Word®	2002	109KB	4 pages
Contents: Evidence Table 88. Composite CVD Mortality; Cohort Studies: type 2 diabetes
________________________________________________________________________________________________
99etbl89.doc	Microsoft Word® Document	MS Word®	2002	26KB	1 page
Contents: Evidence Table 89. Composite CVD Mortality; Randomized Controlled Trials: type 2 
diabetes
________________________________________________________________________________________________
100etb90.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 90. Cause Specific CVD Mortality; Cohort Studies: Myocardial 
Infarction type 1 diabetes
________________________________________________________________________________________________
101etb91.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 91. Cause Specific CVD Mortality; Cohort Studies: Myocardial 
Infarction type 2 diabetes
________________________________________________________________________________________________
102etb92.doc	Microsoft Word® Document	MS Word®	2002	36KB	1 page
Contents: Evidence Table 92. Cause Specific CVD Mortality; Cohort Studies: Cerebrovascular 
Accident, type 1 diabetes
________________________________________________________________________________________________
103etb93.doc	Microsoft Word® Document	MS Word®	2002	28KB	1 page
Contents: Evidence Table 93. Cause Specific CVD Mortality; Cohort Studies: Cerebrovascular 
Accident, type 2 diabetes
________________________________________________________________________________________________
104etb94.doc	Microsoft Word® Document	MS Word®	2002	42KB	2 pages
Contents: Evidence Table 94. CVD Morbidity; Cohort Studies, type 1 diabetes
________________________________________________________________________________________________
105etb95.doc	Microsoft Word® Document	MS Word®	2002	47KB	2 pages
Contents: Evidence Table 95. CVD Morbidity; Cohort Studies, type 2 diabetes
________________________________________________________________________________________________
106etb96.doc	Microsoft Word® Document	MS Word®	2002	48KB	1 page
Contents: Evidence Table 96. CVD Morbidity; Clinical Trials Analyzed as Cohort Studies, 
type 1 and 2 diabetes
________________________________________________________________________________________________
107etb97.doc	Microsoft Word® Document	MS Word®	2002	29KB	1 page
Contents: Evidence Table 97. CVD Morbidity; Randomized Controlled Trials, type 2 diabetes
________________________________________________________________________________________________
108etb98.doc	Microsoft Word® Document	MS Word®	2002	59KB	3 pages
Contents: Evidence Table 98. CVD Morbidity and Mortality; Cohort Studies, type 2 diabetes
________________________________________________________________________________________________
109etb99.doc	Microsoft Word® Document	MS Word®	2002	46KB	1 page
Contents: Evidence Table 99. CVD Morbidity and Mortality; RCT Analyzed as Cohort Study, 
type 1 and 2 diabetes
________________________________________________________________________________________________
110acros.doc	Microsoft Word® Document	MS Word®	2002	43KB	1 page
Contents: Acronyms and Abbreviations
________________________________________________________________________________________________
111gbib.doc	Microsoft Word® Document	MS Word®	2002	128KB	19 pages
Contents: Glycohemoglobin Bibliography
________________________________________________________________________________________________
112ubib.doc	Microsoft Word® Document	MS Word®	2002	76KB	9 pages
Contents: Urine Albumin Bibliography
________________________________________________________________________________________________
113aplst.doc	Microsoft Word® Document	MS Word®	2002	22KB	2 pages
Contents: List of Appendixes
________________________________________________________________________________________________
114appa.doc	Microsoft Word® Document	MS Word®	2002	24KB	2 pages
Contents: Appendix A. Acknowledgments
________________________________________________________________________________________________
115appb.doc	Microsoft Word® Document	MS Word®	2002	67KB	4 pages
Contents: Appendix B. Study Questions: Refinement by Experts
________________________________________________________________________________________________
116appc.doc	Microsoft Word® Document	MS Word®	2002	74KB	3 pages
Contents: Appendix C. Glycohemoglobin (GHb) Testing
________________________________________________________________________________________________
117appd.doc	Microsoft Word® Document	MS Word®	2002	23KB	2 pages
Contents: Appendix D. EDTRS Criteria
________________________________________________________________________________________________
118appe.doc	Microsoft Word® Document	MS Word®	2002	34KB	1 page
Contents: Appendix E. Glycohemoglobin Abstract Review Form
________________________________________________________________________________________________
119appf1.doc	Microsoft Word® Document	MS Word®	2002	1.5MB	45 pages
Contents: Appendix F. Glycohemoglobin and Diabetic Complications: Data Abstraction Tool
________________________________________________________________________________________________
120appf2.doc	Microsoft Word® Document	MS Word®	2002	1.0MB	25 pages
Contents: Appendix F. Glycohemoglobin and diabetic complications: PART II--Results
________________________________________________________________________________________________
121appg.doc	Microsoft Word® Document	MS Word®	2002	37KB	1 page
Contents: Appendix G. Microalbuminuria Abstract Review Form
________________________________________________________________________________________________
122apph1.doc	Microsoft Word® Document	MS Word®	2002	1.4MB	42 pages
Contents: Appendix H. Microalbuminuria and Diabetic Complications: Data Abstraction Tool
________________________________________________________________________________________________
123apph2.doc	Microsoft Word® Document	MS Word®	2002	848KB	21 pages
Contents: Microalbuminuria and diabetic complications: PART II--Results
________________________________________________________________________________________________
124appi.doc	Microsoft Word® Document	MS Word®	2002	25KB	1 page
Contents: Appendix I. Research Team
________________________________________________________________________________________________

AHRQ Publication No. 04-E001
Current as of October 2003


Internet Citation:

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus. File Inventory, Evidence Report/Technology Assessment Number 84. AHRQ Publication No. 04-E001, October 2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/glycainv.htm


Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services